APX 3330

Drug Profile

APX 3330

Alternative Names: APX3330; E-3330

Latest Information Update: 25 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Co Ltd
  • Developer Apexian Pharmaceuticals
  • Class Antivirals; Hepatoprotectants; Quinones; Small molecules
  • Mechanism of Action DNA apurinic apyrimidinic site lyase inhibitors; Protein inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Age-related macular degeneration; Cancer; Haematological malignancies; Peripheral nervous system diseases
  • Discontinued Liver disorders

Most Recent Events

  • 24 Jan 2018 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (PO) (NCT03375086)
  • 06 Jun 2017 Apexian Pharmaceuticals receives SBIR and STTR grant from National Cancer Institute for APX 3330 development in Cancer
  • 01 Mar 2017 The US FDA accepts a protocol for a phase I trial of APX 3330 in Solid tumours to include biomarker measurements and evaluate the tolerability and anti-tumour effects of APX 3330
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top